Spero Therapeutics (SPRO) Depreciation & Amortization (CF) (2016 - 2024)
Spero Therapeutics posted quarterly Depreciation & Amortization (CF) of $2000.0 for Q2 2024, down 98.15% year-on-year from $108000.0 in Q3 2023, and down 94.74% on a QoQ basis from $38000.0 in Q4 2023.
Spero Therapeutics (SPRO) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $2000.0 in Q2 2024.
- For the quarter ending Q2 2024, Depreciation & Amortization (CF) fell 98.15% year-over-year to $2000.0; the trailing twelve-month figure through Mar 2025 stood at $2000.0 (down 99.21% YoY), and the FY2024 full-year result was $2000.0, down 99.46% from the prior year.
- Depreciation & Amortization (CF) for Q2 2024 stood at $2000.0, down from $38000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $294000.0 in Q2 2022 and bottomed at $2000.0 in Q2 2024.
- The 5-year median for Depreciation & Amortization (CF) is $159000.0 (2021), against an average of $157882.4.
- The widest annual swing landed in 2020, when Depreciation & Amortization (CF) jumped 477.05%; it then tumbled 98.15% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $230000.0 in 2020, then declined by 16.96% to $191000.0 in 2021, then sank by 32.46% to $129000.0 in 2022, then slumped by 70.54% to $38000.0 in 2023, then slumped by 94.74% to $2000.0 in 2024.
- The last three Depreciation & Amortization (CF) figures came in at $2000.0 (Q2 2024), $38000.0 (Q4 2023), and $108000.0 (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Sep 30, 2023 | 108,000.00 |
| Sep 30, 2023 | 108,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Sep 30, 2022 | 257,000.00 |
| Sep 30, 2022 | 257,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 189,000.00 |
| Mar 31, 2022 | 189,000.00 |
| Dec 31, 2021 | 191,000.00 |
| Dec 31, 2021 | 191,000.00 |
| Sep 30, 2021 | 148,000.00 |
| Sep 30, 2021 | 148,000.00 |
| Jun 30, 2021 | 148,000.00 |
| Jun 30, 2021 | 148,000.00 |
| Mar 31, 2021 | 159,000.00 |
| Mar 31, 2021 | 159,000.00 |
| Dec 31, 2020 | 230,000.00 |
| Dec 31, 2020 | 230,000.00 |
| Sep 30, 2020 | 191,000.00 |
| Sep 30, 2020 | 191,000.00 |
| Jun 30, 2020 | 190,000.00 |
| Jun 30, 2020 | 190,000.00 |
| Mar 31, 2020 | 189,000.00 |
| Mar 31, 2020 | 189,000.00 |
| Dec 31, 2019 | -61,000.00 |
| Dec 31, 2019 | -61,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 188,000.00 |
| Jun 30, 2019 | 188,000.00 |
| Mar 31, 2019 | 184,000.00 |
| Mar 31, 2019 | 184,000.00 |
| Dec 31, 2018 | 139,000.00 |
| Dec 31, 2018 | 139,000.00 |
| Sep 30, 2018 | 81,000.00 |
| Sep 30, 2018 | 81,000.00 |
| Jun 30, 2018 | 94,000.00 |
| Jun 30, 2018 | 94,000.00 |
| Mar 31, 2018 | 95,000.00 |
| Mar 31, 2018 | 95,000.00 |
| Dec 31, 2017 | 99,000.00 |
| Dec 31, 2017 | 99,000.00 |
| Sep 30, 2017 | 94,000.00 |
| Sep 30, 2017 | 94,000.00 |
| Jun 30, 2017 | 83,000.00 |
| Jun 30, 2017 | 83,000.00 |
| Mar 31, 2017 | 87,000.00 |
| Mar 31, 2017 | 87,000.00 |
| Dec 31, 2016 | 85,000.00 |
| Dec 31, 2016 | 85,000.00 |